- Artificial Intelligence
- Deep Learning
- Medical device
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
Echoliv is a MedTech startup that develops solutions based on artificial intelligence and applied to hepatic ultrasound. Our goal is to develop software to assist radiologists and hepatologists.
We are currently developing an AI solution for the early detection of the main liver cancer, hepatocellular carcinoma (HCC).
Echoliv a été fondée par : Jules Bayet, ingénieur en machine learning, diplômé de l’École Polytechnique ; Victor Neuillet, serial entrepreneur, diplômé de l’ESCP Business School ; Elsa Angelini, experte en machine learning appliquée à l’imagerie médicale avec un doctorat en imagerie biomédicale, professeure-associée à Télécom Paris, Imperial College London et Columbia.
DESCRIPTION OF PRODUCTS / SERVICES / TECHNOLOGY
Echoliv is involved in the diagnosis of early stage HCC. The objective is to concretely bring a gain in specificity and sensitivity in order to increase the number of diagnoses of sick patients and also to reduce positive tests on non-sick patients.
The Echoliv solution is an artificial intelligence-based medical technology for ultrasound. The algorithms analyse and process the images, and detect traces of HCC if present. Radiologists and X-ray manipulators acquire ultrasound videos as in standard practice and thus receive valuable decision support: the algorithm will provide multi-signal identification.
COLLABORATIONS / HIGHLIGHTS
The Echoliv solution will be based on an architecture and know-how developed and tested during academic research on the classification of liver pathology (and particularly HCC).
Echoliv is looking for hospital partners in order to acquire more data and test the solution directly in the hands of radiologists and hepatologists.
In same field
Research & development for an in vitro diagnostic tool for endometriosisDiscover
Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.Discover
Ciclix is a tech driven company specialized in process digitization for hospitals and focused on creating natural and efficient solutions for a variety of user profiles in the hospital environment.Discover
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Biotechnology, R&D, Drug development, oncology, obesity, infectious diseasesDiscover
Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.Discover
Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell DiseaseDiscover
Artificial intelligence to optimize and accelerate the development of gene therapiesDiscover
Production of BCG vaccines and BCG-based cancer and inflammation treatments, preparation and distribution of fresh log-phase BCG cultures.Discover
Software for biomedical data analysisDiscover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).Discover
Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.Discover
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).Discover
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.Discover
LPS-BioSciences is specialized in bacterial endotoxins. It combines an exclusive proprietary technology for endotoxin production and characterization. and its acquired experience in the fields of vaccines, diagnostics, and the food industry.Discover
IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.Discover
Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.Discover
Design, development and commercialization of medical devices and services for the diagnosis of endometriosis.Discover